Khan Arifa S, Ma Hailun, Taliaferro Lanyn P, Galvin Teresa A, Shaheduzzaman Syed
Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD, USA
Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD, USA.
PDA J Pharm Sci Technol. 2014 Nov-Dec;68(6):661-6. doi: 10.5731/pdajpst.2014.01029.
The use of new cell substrates for the development of biologicals, particularly tumorigenic and tumor-derived cell lines, can pose a major regulatory challenge due to safety concerns related to the presence of novel viruses, latent and occult viruses including oncogenic viruses, and endogenous retroviruses, since these may not be detected by the currently recommended conventional assays. This report is a summary of our laboratory's experiences using advanced nucleic acid-based technologies to evaluate a Madin-Darby canine kidney (MDCK) cell line and the insect Sf9 cell line derived from Spodoptera frugiperda, and presents some ongoing efforts to address the challenges of novel virus detection.
使用新的细胞基质来开发生物制品,尤其是致瘤性和肿瘤衍生的细胞系,可能会带来重大的监管挑战,因为存在与新型病毒、潜伏和隐匿病毒(包括致癌病毒)以及内源性逆转录病毒相关的安全问题,而目前推荐的传统检测方法可能无法检测到这些病毒。本报告总结了我们实验室使用先进的基于核酸的技术评估犬肾传代细胞(MDCK)系和源自草地贪夜蛾的昆虫Sf9细胞系的经验,并介绍了为应对新型病毒检测挑战而正在进行的一些工作。